WHO Issues Concern Over Severe Shortage of Weight-Loss Injections
Less than a tenth of people who could benefit from obesity jabs including Wegovy are able to get them, warns the World Health Organization as it publishes its initial recommendations on the drugs.
Considering over a billion individuals worldwide currently living with obesity, it is urging increased and just availability to GLP-1 medication.
Based on estimates, more than two billion will be living with obesity by 2030 if no action is taken.
"Our new guidelines recognises that excess weight is a long-term condition that can be treated with thorough and ongoing treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are major hurdles to widespread access to the injections that can help people shift significant body mass, explains the organization.
GLP-1 Therapy Scarcity
Even in the current most optimistic outlook, the manufacturing of such drugs could only cover around 100 million people – under 10% of eligible patients, per the health organization.
The advice encourages governments and firms to increase availability, via approaches such as voluntary licensing.
The intellectual property rights on a key compound – the main ingredient of a leading brand – is set to lapse in multiple countries in 2026.
The Way Weight-Loss Injections Function
GLP-1 drugs mimick a body's own hormone to reduce digestion speed, reduce hunger and enhance the sense of being full so users eat less.
Individuals commonly begin shedding pounds after several weeks of beginning the weekly injections.
Studies indicates patients may put most of the weight back on within a year of stopping the drug, as their usual appetite resume.
To be overweight or obese raises your risk for contracting diseases, such as type 2 diabetes, cardiovascular issues, brain attack, and some malignancies.
Obesity concerns people in countries worldwide and was linked to millions of deaths worldwide in 2024, according to the WHO.
